HAMPTON, N.J., Jan. 4, 2012 /PRNewswire/ -- Ikaria, Inc., a critical care company focused on developing and commercializing innovative therapies designed to address the significant needs of critically ill patients in the hospital and ICU settings, today announced that its Chairman and CEO, Daniel Tasse, will present at the 2012 Biotech Showcase conference. Mr. Tasse's presentation will be given on Wednesday, January 11, 2012 at 2:00 p.m. PST on the fourth floor of the Parc 55 Wyndham in San Francisco, CA.
About Ikaria, Inc.
Ikaria, Inc. is a critical care company focused on developing and commercializing innovative therapies designed to address the significant needs of critically ill patients in the hospital and ICU settings. Ikaria's therapies are designed to meet the unique and complex medical needs of these critically ill patients. The Company's lead product is INOMAX® (nitric oxide) for inhalation, the only FDA-approved drug for the treatment of hypoxic respiratory failure associated with pulmonary hypertension in term and near-term infants. It is offered through the INOMAX therapy package, an all-inclusive offering of drug product, drug-delivery system, on-site training and 24/7/365 technical assistance and support. Ikaria, alone or through partners, also markets the INOMAX therapy package in Puerto Rico, Canada, Australia, Mexico and Japan. The Company is pursuing a number of new indications for INOMAX. Ikaria's late-stage pipeline also is comprised of LUCASSIN® (terlipressin), a potential treatment for hepatorenal syndrome Type 1; as well as Bioabsorbable Cardiac Matrix (BCM), a potential treatment for preventing cardiac remodeling and subsequent congestive heart failure following acute myocardial infarction. The Company also has a number of investigational compounds in development. Ikaria is headquartered in Hampton, NJ, with a research facility in Madison, WI, and manufacturing facilities in Port Allen, LA and Madison, WI. Please visit www.ikaria.com.
SOURCE Ikaria, Inc.